Home

Search Abstracts

Browse Sessions

Program Committee

Conference Webcasts

Contact Us

---

Session 68   Poster Abstracts Mechanisms of Lymphocyte Dysfunction Wednesday, 1:30 - 3:30 pm Poster Hall

439	HIV-1 Viremia Prevents the Establishment of IL-2-Producing HIV-Specific Memory CD4+T Cells Endowed with Proliferative Capacity S A Younes*1, B Yassine-Diab1, A R Dumont2, R Boulassal2, Z Grossman3, J-P Routy2, and R P Sekaly1,2 1Montreal Univ., Canada; 2McGill Univ., Montreal, Canada; and 3Tel-Aviv Univ., Israel
440	Sustained Decline in T-cell Activation in Patients under Successful HAART is Associated with Higher CD4+ T Cell Gains J M Benito*, M Lopez, S Lozano, P Martinez, J Gonzalez-Lahoz, and V Soriano Madrid, Spain
441	Loss of CD127 Defines a Generalized Memory T-cell Dysfunction in HIV-infected Patients B Cervasi1, M Paiardini1, H Albrecht1, A Muthukumar2, D Sodora2, J D Altman1, M B Feinberg1, and G Silvestri*1 1Emory Univ., Atlanta, GA, USA and 2Univ. of Texas Southwestern Med. Ctr., Dallas, USA
442	Increasing Viral Diversity Following Primary HIV-1 Infection Reflects Positive Selection but Does Not Correlate to Changes in CD4 Counts or Viral Loads D Smith*1, G Hightower1, S Kosakovsky Pond1, C Ignacio1, D Richman1,2, E Daar3, S Little1, and S Frost1 1Univ. of California, San Diego, USA; 2San Diego VA Healthcare Systems, La Jolla, CA, USA; and 3Harbor-UCLA Med. Ctr., Univ. of California, Los Angeles, USA
443	Preferential Apoptosis of HIV-1 Specific CD4+ T cells E Yue, C Kovacs, R Dimayuga, P Parks, and M Ostrowski* Univ. of Toronto, Canada
444	Chronic Immune Activation Leads to T Cell Depletion: a Mouse Model for HIV Pathogenesis M Hazenberg*, S Galkina, G Chkhenkeli, C Stoddart, and M McCune Gladstone Inst. of Virology and Immunology, San Francisco, CA, USA
445	HIV M-tropic Envelope Signaling Through the CCR5 Co-receptor Induces Apoptosis in T Cells A Villasis-Keever*, S Vlahakis, T Gomez, and C Paya Mayo Clinic, Rochester, MN, USA
446	env, Not nef, Is a Cytopathic Determinant of R5 AIDS HIV-1 K Olivieri*1, R Scoggins1, J R Taylor Jr1, A Matthews2, D Charnauskas1, B Brodrick1, M Chmura1, D Rekosh1, M-L Hammarskjold1, and D Camerini2 1Univ. of Virginia, Charlottesville, USA and 2Univ. of California, Irvine, USA
447	High Prevalence of R77Q Vpr Mutation in Long-term Non-progressors from an Italian Cohort of HIV-1-infected Patients D Mologni*1, B Zanone-Poma1, E Gianelli1, G Monolo2, G Quinzan3, L Milazzo1, M Galli1, A Riva1, and r-HoPeS 1Univ. of Milan, Italy; 2ASL di Magenta, Milan, Italy; and 3Hosp. Riuniti, Bergamo, Italy
448	Activation of CD4+ Naïve Lymphocytes Decreases Expression of P-glycoprotein, but Not Multi-drug Resistance Associated Protein 4 M P De Pasquale*, T Allos, L Sutton, A Shintani, S M Grill, D Unutmaz, and R T D’Aquila Vanderbilt Univ. Med. Ctr., Nashville, TN, USA
449	Chemokine Coreceptor Control of TRAIL Induced Apoptosis by gp120 and SDF-1 J J Lum*1, Z Nie2, J Weaver2, H Lee1, D H Lynch3, and A D Badley2 1Univ. of Ottawa, Ontario, Canada; 2Mayo Clinic and Fndn., Rochester, MN.; and 3Amnis Corp., Seattle, WA, USA
450	CD4+ T-cell Depletion in AIDS: Synergy between Non-infectious HIV-1 and Other Viruses Induces Selective Apoptosis via a TRAIL/TRAIL Receptor-dependent Mechanism J P Herbeuval*1, A Boasso1, J D Lifson2, H Yagita3, and G M Shearer1 1NCI, NIH, DHHS, CI, Bethesda, MD, USA; 2AIDS-Vaccine Prgm., NCI-Frederick, MD, USA; and 3Jutendo Univ., Tokyo, Japan
451	Perturbation of CD4+ T Cell Subsets during HIV-1 Infection S Grill1, M Leelawong1, K Richter1, A Motsinger1, T Hulgan1, K Nagata2, D W Haas1, and D Unutmaz*1 1Vanderbilt Univ. Med. Sch., Nashville, TN, USA and 2BML Inc., Res. and Devt. Ctr., Matoba, Kawagoe Saitama, Japan
452	Specific Depletion of CD27+B220- Memory B Cells in HIV Infection M Morrow*1, A Valentin1, R Yarchoan2, and G N Pavlakis1 1NCI at Frederick, NIH, DHHS, MD, MD USA and 2NCI, NIH, DHHS, Bethesda, MD, USA
453	Low-level Antigenic Exposure Differentially Affects T-cell Activation and HIV-specific T-cell Response A Karlsson*1, S Younger1, J Martin2, Z Grossman3, E Sinclair4, P Hunt2, E Hagos2, T Wrin5, C Petropolous5, D Nixon1, and S Deeks2 1Gladstone Inst. of Virology and Immunology, Univ. of California, San Francisco, USA; 2Univ. of California, San Francisco, San Francisco Gen. Hosp., USA; 3Tel-Aviv Univ., Israel and NIH, Bethesda, MD, USA; 4Univ. of California, San Francisco, USA; and 5ViroLogic Inc., South San Francisco, CA, USA